Semaglutide(Zhongshan Wanhan Pharma)

司美格鲁肽（中山万汉制药）

Report date: 2025/12/29 09:31:02

Base Information

Drug NameSemaglutide(Zhongshan Wanhan Pharma)
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhongshan Wanhan Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Jianxiang Biological Pharmaceutical Co LtdZhongshan Wanhan Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A